Deli

Hubei Deli Pharmaceutical Technology Co., Ltd. is a modern high-tech fine chemical enterprise specializing in the research, development, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new materials. Established in March 2019 and headquartered in Songzi City, Hubei Province, China, the company operates an advanced 88,000-square-meter manufacturing facility with a total investment of 300 million RMB. Its core pharmaceutical product portfolio includes key chemical building blocks such as 1,3-dimethylimidazolidinone (DMI), 2-imidazolinone, and N,N-dimethylformamide dimethylacetal (DMF-DMA). The company leverages automated production lines and rigorous quality control systems, adhering to ISO 9001 and ISO 14001 standards to ensure reliable product quality and environmentally sustainable operations. Hubei Deli Pharmaceutical serves a global customer base, offering custom synthesis and technical services to support drug discovery and development pipelines.